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1307nerve palsy, 7 cases of pulmonary vein stenosis > 75%, and even 1
death occurred in the cryoablation arm.Therefore, there is reasonable
doubt regarding the safety of the interventional AF procedures.
Especially in patients with lone AF it is questionable if the beneﬁt of
the AF ablation procedures in fact outweighs their risk. Further
studies are needed to assess the net-beneﬁt of these interventional
procedures. From the pulmonological point of view, serial quanti-
tative lung perfusion scans (3) and serial body plethysmography are
required in further prospective AF ablation trials to assess the long-
term effect of mild to moderate pulmonary vein stenosis and to
assess the loss of vital capacity because of phrenic nerve palsy.*Silke D. Braun, MD
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perfusion imaging. Chest 2004;126:645–51.ReplyCryoBalloon Ablation: First Results
of North American STOP AF
Pivotal Trial
We appreciate very much the letters received regarding the STOP
AF trial (North American Arctic Front). This correspondence has
provided thoughtful considerations regarding ablative intervention in
general, and the cryoballoon STOPAF Trial (1) in speciﬁc. In terms
of safety issues, it is important to reiterate that we elected to include
each and every adverse event that occurred over the course of the 12
months of the trial. Although a single tamponade and infarction
episode occurred at the time of the intervention, the fatal myocardial
infarction occurred at 11 months of follow-up and was unrelated to
the ablative intervention. Of the 5 events reported as strokes, 1 was
related to the ablative intervention in a patient crossing over from
drug therapy. The other 4 events occurred at 183, 51, 30, and 260
days after ablation and were not procedure related. Such late
complications are not typically reported in other trials, but were
included in STOP AF for completeness.
Phrenic nerve injury is a signiﬁcant complication of cryoablation
occurring in 11.2%. In contrast, in the STOP AF Continued
Access Protocol (CAP AF), phrenic nerve palsy (PNP) occurred in3 procedures (3 of 85, 3.5%), with complete resolution in all 3 of
the subjects by the end of follow-up (2). This decrease in occur-
rence is in part because of the increased experience of the operators,
and therefore reﬂects early “real world” experience.
The deﬁnition of pulmonary vein (PV) stenosis, with a > 75%
reduction in cross-sectional area (approximately a 50% reduction in
diameter) used in the trial is nonstandard (3,4). The use of “area”
overestimates the severity of stenosis. A reanalysis of the STOP
AF data using a 70% diameter reduction shows that only 6 of 905
cryoablated veins (0.7%) exceeded this criterion (2). Nevertheless,
there were 2 serious stenoses during the trial, one of which required
intervention, although the other subject refused. The management
of patients with PV stenosis otherwise followed typical approaches
used in the United States and Europe (3,4). In our experience with
PV stenosis, we have found perfusion scans to be of limited value,
although they identify a decrement in perfusion in those patients
with > 65% stenosis (3). We have no experience with body-
plethysmography, nor has this been included in any prior report of
pulmonary vein stenosis or postablation phrenic nerve injury of
which we are aware. This may be an interesting topic for a later
observational study.
Based on these issues addressed in the original STOP AF
manuscript and clariﬁed here, we believe that the safety endpoints of
the trial were appropriately met and reported (1). The safety and
efﬁcacy outcomes of the STOP AF trial are also consistent with the
recent THERMOCOOL Ablation Study (5) and those from
MANTRA-PAF (Medical Antiarrhythmic Treatment or Radio-
frequency Ablation in Paroxysmal Atrial Fibrillation) (6) and
RAAFT 2 (First Line Radiofrequency Ablation versus Antiar-
rhythmic Drugs for Atrial Fibrillation: A Multicenter Randomized
Trial) (7).Additional clinical trialswill be required to establish the long-
term efﬁcacy and safety of AF ablation in patients with underlying
disease, advanced age, and more persistent AF: CABANA (Catheter
Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation
Trial) (NCT00911508); EAST (Early Treatment of Atrial
Fibrillation for Stroke Prevention) (NCT01288352); ATTEST
(Atrial Fibrillation Progression Trial) (NCT01570361).
Several questions were raised in the second letter. In this trial,
there were several patients with “early persistent AF”–deﬁned as
having undergone a single prior cardioversion–included as allowed
in the Food and Drug Administration (FDA)-approved protocol.
The letter correctly identiﬁed that 21 patients had a history of
coronary artery disease, although none had a previous myocardial
infarction.
With regard to the question about antiarrhythmic drug use, the
82 patients randomized to antiarrhythmic drug therapy were
treated with an approved AF treatment drugdpropafenone, ﬂe-
cainide, or sotaloldthat they had not previously failed. The use of
dofetilide and amiodarone were precluded by the U.S. FDA as
a condition of study approval. Had these been available, the overall
drug response rate may have been higher, although these are similar
to the outcome of drug RX in early randomized AF ablation studies
(5). There were, however, 13 cryoablated patients treated with an
antiarrhythmic drug that had been previously ineffective, without
any additional AF after the ablation, thus meeting efﬁcacy criteria
as speciﬁed by the protocol.
We agree with the impact of experience. Even in the STOP AF
Continued Access Protocol, outcomes were better after an incre-
ment in experience (2). As indicated in the current publication, the
STOP AF investigators used this approach without extensive prior
experience, although the STOP AF efﬁcacy outcome is not
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1308signiﬁcantly different from the original reports coming from
Europe and other US clinical trials (1). The ongoing additional
experience does demonstrate shorter procedure times, and in part,
a 30-min trial-speciﬁed waiting period in STOP AF.
We appreciate the commentary regarding approaches to avoiding
phrenic nerve injury. Although we agree this complication is more
likely to occur with smaller cryoballoons, we believe it is critically
related to the relationship between the cryoballoon and pulmonary
vein size. A 23-mm balloon may be appropriate in patients with
small veins. Obviously a 23-mm balloon used in a large vein
contributes to the occurrence of both phrenic nerve injury and PV
stenosis as has been previously established.
Several studies have demonstrated that the outcome with
cryoballoon ablation in patients with persistent AF and those with
signiﬁcant underlying disease is anticipated to be less effective
(8,9). In addition, the single procedure success rate is most appro-
priately compared with the early experience with this balloon system,
rather than recent reports of extended experiences. The efﬁcacy rates
are also similar to recent trials examining RF ablation of AF (5). The
combination of the STOP AF trial with these data demonstrate
an acceptable trajectory as additional experience is acquired. Addi-
tional details regardingminimal temperatures reached, the predictors
of success and failure, and the overall temperature dependence of
cryoablation will be the topics of subsequent manuscripts.
Finally, as indicated, 31 patients underwent repeat cryoballoon
ablation during the blanking period. Each of these had reconnec-
tion of their PVs. One can argue that a longer blanking period
might have demonstrated resolution of recurrent AF in some
patients. Nevertheless, at the time of enrollment in this trial,
a 3-month blanking period was standard. In subsequent trials, it
will be a testable hypothesis that waiting a longer period of time
after ablation might disclose higher success rates than seen with
current approaches. Additional studies comparing current and
emerging technology will require additional consideration.
We are pleased with the opportunity to respond to these ques-
tions, and hope that this allows further clarity of presentation. We
remain convinced that the STOP AF study is a very transparent
presentation of the safety and efﬁcacy outcomes of AF cryoballoon
ablation, and look forward to additional randomized clinical trials
comparing it with PV isolation using RF energy.*Douglas L. Packer, MD
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